Express News | Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of Vp-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...
Verrica Pharmaceuticals Strives for Nasdaq Compliance
Express News | Verrica Pharmaceuticals Inc: As a Result of Craig Ballaron's Resignation, Co Temporarily Not in Compliance With Nasdaq Listing Requirements
Verrica Pharmaceuticals Is Maintained at Outperform by RBC Capital